New approaches to the management of anemia of chronic kidney disease: Beyond Epogen and Infed

Kidney International

Volumn 70, Issue SUPPL. 104, 2006, Pages

  Rastogi, A ^a   Nissenson, A R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Anemia; Chronic kidney disease; Ferumoxytol; Hematide; Iron deficiency; rHuEPO

Indexed keywords

ANABOLIC AGENT; CONTINUOUS ERYTHROPOIESIS RECEPTOR ACTIVATOR; FERUMOXYTOL; IRON; IRON DEXTRAN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; OLIGOSACCHARIDE; PROCOLLAGEN PROLINE 2 OXOGLUTARATE 4 DIOXYGENASE; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; BLOOD TRANSFUSION; BONE MARROW SUPPRESSION; CHRONIC KIDNEY DISEASE; ERYTHROPOIESIS; GENE REPLACEMENT THERAPY; HUMAN; HYPOXIA; INFLAMMATION; IRON DEFICIENCY; KIDNEY DISEASE; NONHUMAN; PRIORITY JOURNAL; SHORT SURVEY;

EID: 33751092506     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/sj.ki.5001970     Document Type: Article

References (11)

1. Lacombe C, Mayeux P. The molecular biology of erythropoietin. Nephrol Dial Transplant 1999; 14(Suppl 2): 22-28.
2. Macdougall IC. CERA (Continuous Erythropoietin Receptor Activator): a new erythropoiesis-stimulating agent for the treatment of anemia. Curr Hematol Rep 2005; 4: 436-440.
3. Osada S, Ebihara I, Setoguchi Y et al. Gene therapy for renal anemia in mice with polycystic kidney using an adenovirus vector encoding the human erythropoietin gene. Kidney Int 1999; 55: 1234-1240.
4. Stead RB, Lambert J, Wessels D et al. Evaluation of the safety and pharmacodynamics of Hematide, a novel erythropoietic agent, in a phase 1, double-blind, placebo-controlled, dose-escalation study in healthy volunteers. Blood 2006; 108: 1830-1834.
5. Duliege AM, Macdougall I, Dancan N et al. Hematide™, a synthetic peptide-based erythropoiesis stimulating agent (ESA), demonstrates erythropoietic activity in a phase 2 single dose, dose escalating study in patients with chronic kidney disease (CKD). Blood 2005; 106: 3532 (abstract).
6. Semenza GL, Agani F, Booth G et al. Structural and functional analysis of hypoxia-inducible factor. 1. Kidney Int 1997; 51: 553-555.
7. Zhu H, Jackson T, Bunn HF. Detecting and responding to hypoxia. Nephrol Dial Transplant 2002; 17(Suppl 1): 3-7.
8. McDonough MA, Li V, Flashman E et al. Cellular oxygen sensing: crystal structure of hypoxia-inducible factor prolyl hydroxylase (PHD2). Proc Natl Acad Sci USA 2006; 103: 9814-9819 (E-pub, 2006 Jun 16).
9. Spinowitz BS, Schwenk MH, Jacobs PM et al. The safety and efficacy of ferumoxytol therapy in anemic chronic kidney disease patients. Kidney Int 2005; 68: 1801-1807.
10. Landry R, Jacobs PM, Davis R et al. Pharmacokinetic study of ferumoxytol: a new iron replacement therapy in normal subjects and hemodialysis patients. Am J Nephrol 2005; 25: 400-410 (E-pub 2005 Jul 28).
11. Gupta A, Amin NB, Besarab A et al. Dialysate iron therapy: infusion of soluble ferric pyrophosphate via the dialysate during hemodialysis. Kidney Int 1999; 55: 1891-1898.